CVS acknowledged that Zepbound has been shown to help people lose more weight than Wegovy, but that Wegovy can still help ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Other changes made in Trump’s sweeping budget and policy bill include the elimination of automatic renewal, more income verification requirements and limiting special enrollment periods.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

MN counties could see strain, 250K could lose coverage under Medicaid changes in Trump’s big bill Added paperwork could drive people to drop coverage, state officials say ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Cursor's CEO issued an apology this weekend over an unclear change to its pricing model that resulted in some users being charged more.